Status:
COMPLETED
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Neovascular Age-related Macular Degeneration of All Subtypes
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
Aflibercept (EYLEA®) induces a rapid reduction in central retinal thickness (CRT) for patients suffering from neovascular age-related-macular degeneration.1 This early dramatic reduction in CRT is alr...
Detailed Description
The aim of this study is to assess whether the retina of some patients has dried up after the first or second intravitreal injection of Aflibercept (EYLEA®) 2mg and in that event, to determine the pro...
Eligibility Criteria
Inclusion
- Men and women ≥ 50 years of age
- Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affects the fovea as evidenced by FA in the study eye
- Signed Informed Consent
- Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
Exclusion
- Prior treatment with anti-VEGF therapy in the study eye
- Active or suspected ocular or periocular infection.
- Active severe intraocular inflammation
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02246829
Start Date
September 1 2014
End Date
June 1 2015
Last Update
November 21 2016
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'ophtalmologie Hôpital Henri Mondor 40, avenue de Verdun
Créteil, France, 94000
2
Service Ophtalmologie CHU DIJON 14 rue Gaffarel BP 77908
Dijon, France, 21079
3
Service d'Ophtalmologie Hôpital de la croix rousse
Lyon, France, 69317
4
Cabinet d'ophtalmologie 1 rue Pougin de la Maisonneuve
Montargis, France, 45200